Investigational new drug, company code: BGG492

DRUG2 trials

Sponsors

Novartis

Conditions

EpilepsyPartial Onset SeizuresSeizures

Phase 2

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

CompletedNCT00887861

NovartisEpilepsy, Seizures

Start: 2009-03-31End: 2010-08-31Updated: 2017-03-21

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

CompletedNCT01147003

NovartisPartial Onset Seizures

Start: 2010-06-30End: 2011-09-30Updated: 2020-12-17